Concepedia

Caroline Sibilla

CS

Statistics

Publications

6

Citations

291

H-Index

6

Active since

2016

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

National Institute of Neurological Disorders and Stroke

Merck & Co., Inc., Rahway, NJ, USA (United States)

BC Cancer Agency

Caroline Sibilla is an author at AstraZeneca (United States) specializing in prostate cancer, genitourinary oncology, and next-generation sequencing in oncology.

ORCID

Publications per year

2016–2022

6

Publications

6

<i>Reep1</i>null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation

Benoît Renvoisé, Brianna Malone, Mélanie Falgairolle et al. · Human Molecular Genetics · 2016 · 88 citations · Full text

, , +13

Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N., Alan Barnicle, Caroline Sibilla et al. · Clinical Cancer Research · 2022 · 71 citations · Full text

, , +17

Clueless/CLUH regulates mitochondrial fission by promoting recruitment of Drp1 to mitochondria

Huan Yang, Caroline Sibilla, Raymond Liu et al. · Nature Communications · 2022 · 53 citations · Full text

, , +15

Prion‐like protein aggregates exploit the RHO GTPase to cofilin‐1 signaling pathway to enter cells

Zhen Zhong, Laura Grasso, Caroline Sibilla et al. · The EMBO Journal · 2018 · 41 citations · Full text

, , +13

Concordance of <i>BRCA1</i>, <i>BRCA2</i> (BRCA), and <i>ATM</i> mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.

Kim N., Alan Barnicle, Caroline Sibilla et al. · Journal of Clinical Oncology · 2021 · 27 citations

, , +17

1–5 of 6